{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:58:48Z","timestamp":1775019528277,"version":"3.50.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Heart J"],"published-print":{"date-parts":[[2015,9,21]]},"DOI":"10.1093\/eurheartj\/ehv174","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T00:42:07Z","timestamp":1431564127000},"page":"2415-2424","source":"Crossref","is-referenced-by-count":98,"title":["PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future"],"prefix":"10.1093","volume":"36","author":[{"given":"Yuichi J.","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"2015092100425796000_36.36.2415.1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.159350"},{"key":"2015092100425796000_36.36.2415.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.366"},{"key":"2015092100425796000_36.36.2415.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.959247"},{"key":"2015092100425796000_36.36.2415.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2015092100425796000_36.36.2415.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-006-0403-x"},{"key":"2015092100425796000_36.36.2415.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.10.042"},{"key":"2015092100425796000_36.36.2415.7","doi-asserted-by":"publisher","DOI":"10.1042\/bse0380079"},{"key":"2015092100425796000_36.36.2415.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0335507100"},{"key":"2015092100425796000_36.36.2415.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2003.09.011"},{"key":"2015092100425796000_36.36.2415.10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M409699200"},{"key":"2015092100425796000_36.36.2415.11","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb1235"},{"key":"2015092100425796000_36.36.2415.12","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"2015092100425796000_36.36.2415.13","doi-asserted-by":"publisher","DOI":"10.1002\/humu.9383"},{"key":"2015092100425796000_36.36.2415.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-005-0019-z"},{"key":"2015092100425796000_36.36.2415.15","doi-asserted-by":"publisher","DOI":"10.1097\/01.mol.0000162321.31925.a3"},{"key":"2015092100425796000_36.36.2415.16","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2006.038356"},{"key":"2015092100425796000_36.36.2415.17","doi-asserted-by":"publisher","DOI":"10.1038\/ng1509"},{"key":"2015092100425796000_36.36.2415.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"2015092100425796000_36.36.2415.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.02.044"},{"key":"2015092100425796000_36.36.2415.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.08.039"},{"key":"2015092100425796000_36.36.2415.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.108.828467"},{"key":"2015092100425796000_36.36.2415.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.03.009"},{"key":"2015092100425796000_36.36.2415.23","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.194191"},{"key":"2015092100425796000_36.36.2415.24","doi-asserted-by":"publisher","DOI":"10.1086\/507488"},{"key":"2015092100425796000_36.36.2415.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903849106"},{"key":"2015092100425796000_36.36.2415.26","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.3524"},{"key":"2015092100425796000_36.36.2415.27","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M011445"},{"key":"2015092100425796000_36.36.2415.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805434105"},{"key":"2015092100425796000_36.36.2415.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61914-5"},{"key":"2015092100425796000_36.36.2415.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010682"},{"key":"2015092100425796000_36.36.2415.31","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.C600025-JLR200"},{"key":"2015092100425796000_36.36.2415.32","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.260"},{"key":"2015092100425796000_36.36.2415.33","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-013-0391-1"},{"key":"2015092100425796000_36.36.2415.34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702027200"},{"key":"2015092100425796000_36.36.2415.35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708098200"},{"key":"2015092100425796000_36.36.2415.36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29383"},{"key":"2015092100425796000_36.36.2415.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.04.004"},{"key":"2015092100425796000_36.36.2415.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409736102"},{"key":"2015092100425796000_36.36.2415.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501652102"},{"key":"2015092100425796000_36.36.2415.40","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.091280"},{"key":"2015092100425796000_36.36.2415.41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2014","journal-title":"Atherosclerosis"},{"key":"2015092100425796000_36.36.2415.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105803"},{"key":"2015092100425796000_36.36.2415.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.007"},{"key":"2015092100425796000_36.36.2415.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61770-X"},{"key":"2015092100425796000_36.36.2415.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.986"},{"key":"2015092100425796000_36.36.2415.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201832"},{"key":"2015092100425796000_36.36.2415.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"2015092100425796000_36.36.2415.48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4030"},{"key":"2015092100425796000_36.36.2415.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.06.049"},{"key":"2015092100425796000_36.36.2415.50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.007012"},{"key":"2015092100425796000_36.36.2415.51","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"2015092100425796000_36.36.2415.52","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"2015092100425796000_36.36.2415.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.12.024"},{"key":"2015092100425796000_36.36.2415.54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01405.x"},{"key":"2015092100425796000_36.36.2415.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.07.035"},{"key":"2015092100425796000_36.36.2415.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.09.014"},{"key":"2015092100425796000_36.36.2415.57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2015092100425796000_36.36.2415.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.03.046"},{"key":"2015092100425796000_36.36.2415.59","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000457464.79076.2c"},{"key":"2015092100425796000_36.36.2415.60","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.6.7.955"},{"key":"2015092100425796000_36.36.2415.61","unstructured":"ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. http:\/\/www.abstractsonline.com\/pp8\/#!\/3547\/presentation\/49567 (28 April 2015)."},{"key":"2015092100425796000_36.36.2415.62","first-page":"2118","article-title":"Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II","volume":"130","author":"Bays","year":"2014","journal-title":"Circulation"},{"key":"2015092100425796000_36.36.2415.63","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies. http:\/\/www.escardio.org\/congresses\/esc-2014\/congress-reports\/Pages\/707-3-Hotline3-ODYSSEY-COMBO-FH.aspx#presenter2 (28 April 2015).","DOI":"10.1007\/s10557-014-6523-z"},{"key":"2015092100425796000_36.36.2415.64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.18553\/jmcp.2005.11.4.300","article-title":"Total first-year costs of acute coronary syndrome in a managed care setting","volume":"11","author":"Etemad","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"2015092100425796000_36.36.2415.65","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101281"},{"key":"2015092100425796000_36.36.2415.66","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-006-0049-z"},{"key":"2015092100425796000_36.36.2415.67","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903494934"},{"key":"2015092100425796000_36.36.2415.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"2015092100425796000_36.36.2415.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.056"},{"key":"2015092100425796000_36.36.2415.70","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.84"},{"key":"2015092100425796000_36.36.2415.71","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/00325481.2015.998987","article-title":"Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin\/kexin type 9 monoclonal antibody: A Phase II pooled analysis","volume":"127","author":"Koren","year":"2015","journal-title":"Postgrad Med"},{"key":"2015092100425796000_36.36.2415.72","doi-asserted-by":"publisher","DOI":"10.3390\/nu6125517"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/36\/36\/2415\/17355469\/ehv174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T02:29:57Z","timestamp":1651976997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehv174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":72,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2015,9,21]]},"published-print":{"date-parts":[[2015,9,21]]}},"alternative-id":["10.1093\/eurheartj\/ehv174"],"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehv174","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}